Gosselies, Belgium, 17 APRIL 2026 (08:30 CET) – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory ...
Final results of BIRCH multicenter, randomized, open-label Phase 2a proof-of-concept BIRCH trial with 23 patients, conducted in Belgium Final results build on positive second interim results announced ...
The MarketWatch News Department was not involved in the creation of this content. -- Three world-leading key opinion leaders, researchers and clinicians, join Clinical Advisory Board, reinforcing ...
Bioxodes reported positive BIOX-101 Phase 2a clinical proof of concept data in ICH patients and is currently preparing to initiate a Phase 2b/3 adaptive trial in ICH and as well as Phase 2 trials of ...
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) today provided preliminary revenues, gross profit and adjusted EBITDA for the fiscal second quarter, ended December 31 ...
XChat, X’s stand-alone messaging app, launched to the public on Friday. Initially available on iOS devices, the new app allows users to connect with their X contacts for messaging, file sharing, audio ...
Launched in 2021, when the company was still known as Twitter, Communities were meant to provide the social network’s users with a place to connect with each other around shared interests. Now, X is ...
Forbes contributors publish independent expert analyses and insights. Kate O’Flaherty is a cybersecurity and privacy journalist. People are quitting X, formerly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results